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Abstract
Background: Although many symptoms of Major Depressive Disorder (MDD) are assessed through patient-report,
there are currently no patient-reported outcome (PRO) instruments that incorporate documented evidence of
patient input in PRO instrument development. A review of existing PROs used in MDD suggested the need to
conduct qualitative research with patients with MDD to better understand their experience of MDD and develop
an evaluative instrument with content validity. The aim of this study was to develop a disease-specific
questionnaire to assess symptoms important and relevant to adult MDD patients.
Methods: The questionnaire development involved qualitative interviews for concept elicitation, instrument
development, and cognitive interviews to support content validity. For concept elicitation, ten MDD severity-
specific focus group interviews with thirty-eight patients having clinician-confirmed diagnoses of MDD were
conducted in January 2009. A semi-structured discussion guide was used to elicit patients’ spontaneous
descriptions of MDD symptoms. Verbatim transcripts of focus groups were coded and analyzed to develop a
conceptual framework to describe MDD. A PRO instrument was developed by operationalizing concepts elicited in
the conceptual framework. Cognitive interviews were carried out in patients (n = 20) to refine and test the content
validity of the instrument in terms of item relevance and comprehension, instructions, recall period, and response
categories.
Results: Concept elicitation focus groups identified thirty-five unique concepts falling into several domains: i)
emotional, ii) cognitive, iii) motivation, iv) work, v) sleep, vi) appetite, vii) social, viii) activities of daily living, ix) tired/
fatigue, x) body pain, and xi) suicidality. Concept saturation, the point at which no new relevant information
emerges in later interviews, was achieved for each of the concepts. Based on the qualitative findings, the PRO
instrument developed had 15 daily and 20 weekly items. The cognitive interviews confirmed that the instructions,
item content, and response scales were understood by the patients.
Conclusions: Rigorous qualitative research resulted in the development of a PRO measure for MDD with
supported content validity. The MDD PRO can assist in understanding and assessing MDD symptoms from patients’
perspectives as well as evaluating treatment benefit of new targeted therapies.
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Major Depressive Disorder (MDD) is a highly prevalent
and disabling psychiatric illness affecting an estimated 13
to 14 million Americans each year [1-4]. Patients with
MDD suffer from persistent depressed mood that
adversely affects all aspects of their life - personal, social,
and economic. It is associated with a 23-fold increase in
the risk of social disability, after controlling for physical
diseases [5]. The impact of this disorder also imposes tre-
mendous social and economic burden on society [6].
MDD is the fourth leading cause of disability in the
world [7] and is considered to be the mental illness with
the largest disease burden on the general population [8].
Patients with MDD show long-term limitations in
functioning and well-being that are similar to or worse
than those of patients with chronic medical illnesses [9].
Data from the National Institutes of Mental Health
(NIMH) Epidemiological Catchment Area Program
found that subjects with MDD reported greater financial
strain, limitations in physical or occupational functioning,
and poorer health status than subjects without MDD
[10]. Epidemiologic studies have found that community
workers with depression were at least five times more
likely to miss work than workers with no symptoms of
depression [11,12]. Depressed primary care patients miss
two to four more days of work per month due to disabil-
ity than patients without depression [12].
The diagnosis of MDD, based on the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
Text Revision (DSM-IV TR), requires: 1) the presence of
a single or recurrent major depressive episode (MDE);
2) that MDEs are not better accounted for by schizoaffec-
tive disorder and are not superimposed on schizophrenia;
and 3) there is no history of manic, mixed, or hypomanic
episodes [13]. Thus, the diagnostic action occurs by
assessing symptoms that characterize an MDE; these
symptoms of depression include depressed mood (such
as feelings of sadness or emptiness), reduced interest in
activities that were previously enjoyed, weight loss or
change in appetite, sleep disturbances, psychomotor agi-
tation or retardation, loss of energy, feelings of guilt or
worthlessness, difficulty concentrating, and suicidal
thoughts or ideations. Furthermore, a single MDE
requires that a patient has experienced at least five of the
aforementioned symptoms, one of which must include
depressed mood or loss of interest or pleasure, for at
least two weeks, and that the symptoms are not a result
of the physiological effects of a substance, medical condi-
tion, or bereavement. Diagnosis for recurrent MDD
requires the presence of two or more MDEs in which the
episodes are separated by an interval of at least two
consecutive months [13].
Severe depression is further categorized as “severe
without psychotic features,” where patients display most
of the diagnostic symptoms accompanied by a marked
disability. Patients displaying signs of hallucinations or
delusions are categorized as “severe with psychotic fea-
tures” [13]. It is estimated that about one third of all
outpatients diagnosed with depression are severely
depressed [14]. The personal, social, and economic
impact of MDD worsens as severity of depression
increases. Severe depression is associated with increased
risk of disability, decreased work productivity, and
higher utilization of health care services [8,15,16].
Several clinician rating scales are presently used in
assessment of symptoms and management of patients
with depression. The Hamilton Depression Rating Scale
(HAM-D) and Montgomery-Åsberg Depression Rating
Scale (MADRS) are widely used clinician-rated scales.
The Inventory of Depressive Symptomatology (IDS); its
shortened version, the Quick Inventory of Depressive
Symptomology (QIDS) [17]; and the Beck Depression
Inventory (BDI-II) are among commonly used patient-
reported measures for depression symptoms [18-21].
Many of these instruments were developed without
patient input and were derived directly from clinician rat-
ing scales, only changing the perspective from clinician to
patient. The Food and Drug Administration (FDA),
which approves drugs and their labels, has suggested that
patient-reported outcomes (PROs) should be developed
with input from patients [22]. As defined by the FDA, a
PRO is any data reported directly by a patient without
interpretation of the patient’s response by a clinician or
anyone else within the context of the condition or its
therapy [22,23]. As health status measures, PROs have
been used to assess treatment benefit and monitor
change in health status as well as in public health
research [24]. Development of a PRO requires rigorous
and transparent qualitative research methods, and equally
rigorous quantitative methods are required to test its
reliability, validity, and responsiveness [22]. In addition,
some of the currently used scales, such as the BDI-II,
have other limitations with respect to their use to estab-
lish treatment benefit; for example, the BDI-II was origin-
ally developed as a screener and as such may not be able
to detect change; it has a two-week recall period, which
may affect its reliability in patient populations with differ-
ent levels of severity; and the response options are not
mutually exclusive, potentially causing problems in
scoring.
The profound impact that MDD has on patients’ lives
underscores the need for additional investigations into
symptoms of MDD. The perspective of patients is crucial
in identifying what symptoms are relevant to their daily
lives and how they are affected by MDD at different
levels of severity. The objective of this cross-sectional
study was to develop a patient-reported questionnaire
that captures the experience of patients with MDD. This
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changes in those symptoms, such as improvement or
deterioration; and associated functional status. This arti-
cle reports the results of this study and introduces a
newly developed PRO to monitor and evaluate treat-
ments of MDD.
Methods
Research procedure
Focus groups were conducted based on the principles of
grounded theory, which seeks to produce spontaneously
elicited, rich descriptions of the symptoms and impacts of
MDD. With this approach, the concepts emerge from
patients’ input, allowing the voice of the patient to be
heard rather than applying an a priori theoretical model
or constructs to interpret the data [25-29]. A focus group
methodology was chosen because breadth, rather than
depth, of the concepts was desired [24]. An open-ended,
semi-structured interview guide was used to generate dis-
cussion amongst the focus group members. A typical
open-ended question for the focus group guide was,
“Please tell me what living with depression means to you.”
Each focus group, conducted in US English and lasting
from 90 to 120 minutes, was homogeneous with regard to
severity levels. Each group was facilitated by a moderator
and a co-moderator; facilitators included a clinical psy-
chologist who acted as moderator or co-moderator in all
focus groups, a medical sociologist with more than twenty
years of experience in qualitative research, and trained
senior researchers. Mock focus groups between team
members were conducted before the actual focus groups,
in order to review the focus group guide and to ensure
good interviewing practice. From the concepts elicited, a
PRO for MDD was developed; PRO items were developed
for concepts or themes of depression symptoms that
emerged from the qualitative data obtained from the focus
groups. The wording for each item was crafted to closely
match the original patient-reported data, in order to retain
the language patients used to describe their experiences.
An 11-point numeric rating scale from “n o ta ta l l ” to
“extremely” or “none of the time” to “all of the time” was
added to measure each item. This specific response scale
was selected due to the ability to detect variability in
change over time (responsiveness) using a wider distribu-
tion. While not specifically interval in nature, all 11 point
NRS allows for distribution-based responsiveness estima-
tions [30]. Figure 1 presents a diagram of the development
of the MDD PRO.
Content validity testing
The new PRO was tested for content validity in cogni-
tive interviews (CIs) that addressed each of the items
[31]. CIs were face-to-face, as is standard for this type
of interview, where the desired outcome is depth to
confirm content validity (as intended by the developer),
comprehensibility, relevance, readability, and that the
recall period and the fit between item stems and
responses are appropriate [22]. Twenty individual in-
depth CIs were conducted using open-ended and prob-
ing questions. These interviews included a brief, open-
ended concept elicitation component to determine the
comprehensiveness of concepts important to patients
with MDD. All interviewers were trained using Mapi
Values’ intensive interviewer training regimen. Addi-
tional training specific to this study included conducting
a mock interview with feedback from the project team.
The PRO was cognitively debriefed to determine the
understandability, relevance, and interpretability of the
items and their response options and any modifications
following the results of each iterative set of interviews.
A typical question and its probe on the CI interview
guide were worded as follows:
Question 1: In the past 24 hours, how irritable have
you felt?
1. What does the question mean to you? [Note: If
patient repeats the question verbatim, ask the patient to
describe an experience.]
a. What does “irritable” mean to you?
To query about response options, the following ques-
tion was asked during the CIs:
1. What made you choose [Response selected by
patient]?
In addition, these interviews assessed the appropriate-
ness of the recall period and the understanding of instruc-
tions. First, 10 patient interviews were conducted, after
which modifications were made to the PRO. Then this
modified version was tested with a second set of five
patients and revised once again. Finally this revised version
was tested with five additional patients.
All focus group and CIs were transcribed verbatim.
Participants/patients
Subjects were men and women between the ages of 18
and 65, diagnosed with MDD as defined by the DSM-IV
TR criteria, with the aim of capturing patients’ experi-
ence with episodes of MDD. The study population for
both the focus group and CIs was chosen to reflect
severity levels to capture any cross-sectional differences
between symptoms and function within those levels.
The inclusion criteria included: outpatient between the
ages of 18 years and 65 years old; a current clinical diag-
nosis of MDD according to DSM-IV criteria, confirmed
by the treating clinician; if diagnosed with comorbid
Generalized Anxiety Disorder (GAD), MDD as the pri-
mary diagnosis; and fluent US English speaker and will-
ing and able to read, comprehend, and sign an informed
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tory of DSM-IV Axis I disorder(s) other than MDD,
with the exceptions of GAD, comorbid panic disorder,
and simple phobias; a DSM-IV Axis II disorder that has
a major impact on the patient’s current psychiatric
status; a DSM-IV Axis II borderline or antisocial per-
sonality disorder; a lifetime history of schizophrenia,
bipolar, psychosis, or psychotic depression; considered a
treatment-refractory patient (defined as having failed
adequate courses of treatment with four or more
Data Set I 
Concept elicitation focus groups (n=10) with: 
–  15 subjects with severe depression 
–  8 subjects with moderate depression 
–  7 subjects with mild depression 
–  8 subjects in remission 
Ø 
Pre-Coding 
Initial code book developed 
–  Root concept codes (i.e., symptoms or impacts) 
–  Dimension codes (e.g., severity and frequency) 
Sensitizing concepts to the code book added and based on: 
–  Word review in transcripts 
–  Coding of the first transcript 
Ø 
Coding 
Iterative harmonization of the code book to produce reliable coding scheme 
Transcripts coded and coding reviewed 
Code book refined as new concepts emerge, or merging of codes as needed based on linguistically or conceptual equivalence 
Ø 
Analyses 
All coded quotations reviewed to compare and contrast concepts and their dimensions across participants and groups 
Frequency of the occurrence of each concept  
Synthesis of findings to distinguish between simple concepts and multidimensional concepts given participants’ meaning and importance attributed to concepts 
Sample size confirmed as sufficient to obtain a comprehensive list of symptoms related to MDD (concept saturation and domain comprehensiveness) 
Coding scheme and conceptual framework reviewed by clinician for clinical relevance of concepts 
Ø 
Conceptual Framework 
Ø 
Item Generation 
New items generated to reflect the conceptual framework by PRO development and clinical experts 
Ø 
2
nd Data Set  
Iterative cognitive interviews with 20 patients 
–  2 subjects with severe depression 
–  7 subjects with moderate depression 
–  7 subjects with mild depression 
–  4 subjects in remission 
Brief concept elicitation and debriefing of 35 items 
Ø 
Coding and Analysis 
Interviews coded for comprehensiveness of concepts 
Items coded for 
–  Interpretability of items and instructions 
–  Appropriate recall period 
–  Fit between item stem and response options 
– Clarity  of  words 
Ø 
Finalization of Major Depressive Disorder Patient Reported Outcome Measure 
15 Daily Items (24-hour recall period) 
20 Weekly items (7-day recall period) 
Figure 1 Qualitative Research Overview.
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use of depot antipsychotics; a history of substance or
alcohol abuse in the past six months or dependence
w i t h i nt h ep a s ty e a r( e x c e p tf o rc a f f e i n eo rn i c o t i n e
dependence), as defined by DSM-IV criteria; currently
pregnant or lactating; and cognitive impairment that
would interfere with participation in a 90-minute focus
group or interview.
“Mini” focus groups were recruited to ensure the size of
the focus group would allow all participants to participate
and that the groups would not be so large as to be over-
whelming to a vulnerable population. Non-probabilistic
purposive sampling was used to recruit four focus groups
(three to four patients per group) with severe MDD (n =
15), two groups (four patients per group) with moderate
depression (n = 8), two groups (three to four patients per
group) with mild MDD, and two groups (four patients per
group) in remission (n = 8). As there is currently no stan-
dardized definition of the varying MDD severity levels,
inclusion of subjects across MDD severity level relied on
clinician’s rating of subjects’ current severity level through
completion of an overall severity of depression assessment.
Clinicians were instructed to classify subjects as having
severe, moderate, or mild MDD or as being in remission
(partial or full), using the DSM-IV criteria. This informa-
tion was attached to the Case Report Form completed by
the clinician. The treating clinician (a psychiatrist or pri-
mary care physician) made the assessment of the severity
of MDD.
Recruitment and institutional review board approval
Subjects were recruited by a commercial agency, Global
Market Research Group, through a database of clinicians
(including primary care physicians and psychiatrists), who
were required to confirm the diagnosis of MDD. Each
clinician attributed the subject to one of the five severity
groups (i.e., severe, moderate, and mild depression and in
partial or full remission) based on a global assessment of
condition severity. The Copernicus Group Independent
Review Board approved the study and study documents.
Each patient had to meet the inclusion and exclusion cri-
teria that were included in the Case Report Form, and
each patient was diagnosed by his/her clinician, who
signed the Case Report Form. The same procedures were
used to recruit and confirm diagnoses for the CIs. Each
p a t i e n ts i g n e da ni n f o r m e dc o n s e n tf o r ma n dH e a l t h
Insurance Portability and Accountability Act of 1996
(HIPAA) forms and received a stipend of US$125 for their
participation. Subjects were assured of confidentiality
through deidentification of the data.
Setting
Focus groups were conducted at commercial non-clini-
cal and clinical facilities in Philadelphia, New York,
Boston, Atlanta, and Chicago. CIs were held at commer-
cial non-clinical facilities in California, Minnesota, and
Louisiana. Procedures and interviews guides were con-
sistent across all sites and severity groups.
Coding and analysis
ATLAS.ti Version 6.0, a computerized qualitative data
analysis package, was used to code and analyze the
data [28]. A coding scheme including key symptoms
and impacts and dimension descriptors (e.g., fre-
quency, severity, duration, pattern, triggers) was itera-
tively developed by the research team and was
modified as analysis progressed to reflect emerging
concepts or to merge conceptually equivalent codes
[32,33]. Initially, one transcript was coded by all the
same project team members who had also conducted
the interviews to develop the coding scheme. Harmoni-
zation of the coding scheme was accomplished through
research team discussion when disputes arose, and this
process continued until all transcripts had been coded.
Each transcript was independently coded by one of
four coders; coding was reviewed by senior members
of the team to ensure consistency and reliability of the
coding process.
At the end of the coding process, patterns in the data
were determined. Interpretation of the data was performed
using a constant comparison method. This process
allowed patients’ quotes to be compared and contrasted
among and between focus groups to identify recurrent
concepts relevant to the symptoms and effect of
those symptoms on the function of patients with MDD.
Concepts that pertained to the same phenomenon were
grouped into general domains. See Figure 2 for a concep-
tual framework showing how items, concepts, and
domains are related [22]. To ensure the clinical relevance
of concepts in the conceptual framework, the conceptual
framework and its development process were reviewed by
a clinician (JE). To ensure the adequacy of the sample size
and that sufficient data were collected to document ela-
boration of the concepts and dimensions that constitute
the conceptual framework, concept saturation was
assessed by documenting concept emergence across sets
of successive interviews [26,27]. Concept saturation is
achieved when further interviews would be unlikely to eli-
cit new, important, and clinically relevant concepts.
Concepts important to subjects suffering from MDD
were identified and compared and contrasted according
to MDD severity levels. Concepts that emerged from the
focus group discussions highlighted the complex sympto-
matology of MDD and its associated impact on subjects’
health-related quality of life. Due to the nature of mental
health disorders, the classification of a spontaneously
reported concept as a symptom or impact of MDD was
challenging and was achieved only through counsel from
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tion was initially coded as a symptom of MDD but then
reclassified as an impact of MDD, as impaired concentra-
tion appeared to be a direct and measurable activity
impacted by the symptoms. To distinguish between
symptoms and impacts, the research team followed the
following definitions: changes in subjective feelings, idea-
tion, impulses, or desires (e.g., “Iw a n tt ob ea l o n e ”)w e r e
identified as symptoms; and changes in psychosocial
behavior (e.g., social relationships, work function,
Item    Concept    General Domain 
In the past 24 hours, how irritable have you felt?  →  irritable  → 
Emotional 
In the past 24 hours, how much of the time did you not enjoy activities that you used to like to do?  →  lack of pleasure  → 
In the past 24 hours, how helpless have you felt?  →  helpless  → 
In the past 24 hours, how angry have you felt?  →  angry  → 
In the past 24 hours, how much of the time have you felt like crying?  →  crying  → 
In the past 24 hours, how sad have you felt?  →  depressed/sad  → 
In the past 24 hours, how overwhelmed have you felt?  →  overwhelmed  → 
In the past 24 hours, how hopeless have you felt?  →  hopelessness  → 
In the past 7 days, how guilty have you felt?  →  guilt  → 
In the past 24 hours, how much of the time have you felt a lack of energy?  →  lack of energy  → 
In the past 24 hours, how anxious have you felt?  →  anxiety  → 
         
In the past 24 hours, how much of the time have you spent dwelling on the negative?  → 
negative 
perceptions/thoughts  → 
Cognitive 
In the past 7 days, how difficult has it been for you to concentrate (for example, while reading, 
watching TV, during conversations)?  →  concentration/focus  → 
In the past 7 days, how difficult has it been for you to remember (for example, names, tasks, events)?  →  memory  → 
In the past 7 days, how difficult has it been for you to think clearly?  →  clarity of thought  → 
In the past 7 days, how difficult has it been for you to make decisions?  →  indecisive  → 
In the past 7 days, how much of the time have you lacked confidence in yourself?  →  self-image  → 
         
In the past 24 hours, how much have you had to push yourself to do activities?  → 
need to push oneself to do 
things  →  Motivation 
         
In the past 7 days, how difficult has it been for you to engage in paid or unpaid work?  →  work  →  Work 
         
In the past 7 days, how much has your sleep decreased?  →  increased sleep  → 
Sleep  In the past 7 days, how much has your sleep increased?  →  decreased sleep  → 
In the past 7 days, how much of the time did you wake up from sleep feeling rested?  →  not restful sleep  → 
         
In the past 7 days, how much has your appetite decreased?  →  increased appetite  → 
Appetite 
In the past 7 days, how much has your appetite increased?  →  decreased appetite  → 
         
In the past 7 days, how difficult has it been for you to interact with close family members?  →  family interaction  → 
Social 
In the past 7 days, how difficult has it been for you to interact with your friends?  →  friends  → 
In the past 7 days, how much of the time have you felt like avoiding other people?  →  felt like avoiding others  → 
In the past 7 days, how much of the time have you wanted to be left alone?  →  wanting to be left alone  → 
         
In the past 24 hours, how difficult has it been for you to take care of yourself (for example, showering, 
shaving, brushing/combing your hair)?  →  self-care  → 
Activities of daily living 
In the past 7 days, how difficult has it been for you to do household activities (for example, dishes, 
laundry, taking the garbage out)?  →  household activities  → 
         
In the past 24 hours, how tired have you felt during the daytime?  →  tired  →  Tired/fatigue 
         
In the past 24 hours, how would you rate your body aches?  →  aches  →  Body Pain 
         
In the past 7 days, how much of the time have you thought about death?  →  thoughts of death  → 
Suicidality  In the past 7 days, how much of the time have you thought about taking your own life?  → 
thoughts of own  
death/suicide  → 
In the past 7 days, how much of the time have you spent making plans to take your life?  →  suicide plans/attempts  → 
Figure 2 Conceptual Framework of Major Depressive Disorder Patient-Reported Outcome Measure -Daily and Weekly.
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ities impacted by the symptoms.
Results
Study population
Thirty-eight patients were recruited for the concept elici-
tation study. Forty subjects were scheduled; however, two
subjects did not show. One subject left mid-focus group
session due to discomfort in the group setting (he was
the only male in the group of four); his data, up to the
point of his departure, was deemed useful to include in
the analysis (the subject also completed the demographic
and health information form via mail). Twenty-six
women (68%) and 12 men (32%) participated in the con-
cept elicitation interviews. Seventy-six percent of the sub-
jects were Caucasian, and all patients had a high school
education or its equivalent. Fifteen subjects were diag-
nosed with severe, eight with moderate, and seven with
mild depression; eight subjects were in remission.
Twenty patients participated in the CIs; their ages ran-
ged from 26 to 74, with a mean age of 44 (standard devia-
tion [SD] = 13.5). Most patients were female (n = 17,
85%) and Caucasian (n = 13, 65%). Eight patients (40%)
were working full- or part-time. Two patients were diag-
nosed with severe, seven with moderate, and seven with
mild depression; four patients were in remission. See
Table 1 for a more detailed description of the demo-
graphic details for the focus groups and CIs and Table 2
for detailed information about their health status.
Concepts elicited and development of MDD PRO
Sixty seven (67) distinct concepts were elicited, analyzed,
and merged based on conceptual equivalence (e.g., anxi-
ety and panic) and clinical validity (e.g., obsessive and
negative thoughts). The final list included 35 concepts
that were grouped into 11 general domains. These
included: i) emotional (11 concepts such as angry and
helpless), ii) cognitive (six concepts including memory
and clarity of thought), iii) motivation, iv) work, v) sleep
(three concepts), vi) appetite (two concepts), vii) social
(four concepts), viii) activities of daily living (two con-
cepts), ix) tired/fatigue, x) body pain, and xi) suicidality
(three concepts). All concepts but three (i.e., engage in
intimacy, ability to articulate, and clear-headed) were
saturated. Items were generated to reflect each of the 35
concepts. These concepts resulted in 15 daily and 20
weekly items, (i.e., recall periods of the “past 24 hours”
and “past seven days,” respectively). Thirty-two items
used an 11-point severity or frequency numerical rating
scale response format. One item asked for the number
of hours of sleep in the past 24 hours, and one item
asked, “How would you rate the amount of sleep you
had in the past twenty-four hours?” with the responses,
“less than I would have liked,”“ about the right amount,”
and “more than I would have liked.” One item asked
“How would you rate the amount you have eaten in the
past twenty-four hours?” with responses, “less than I
would have liked,”“ a b o u tt h er i g h ta m o u n t , ” or “more
than I would have liked.”
F o u ro ft h em o s tf r e q u e n tc o n c e p t sr e p o r t e dw e r e
“avoidant” (n = 34), “self-image/confidence” (n = 30),
“thoughts of death” (n = 25) and “suicidal ideation” (n =
25). Subjects across all severity groups avoided others
when depressed. Subjects used the words, “isolate,”
“tune out,”“ not a people person,”“ hide from the
world,”“ shut people out,”“ shut down,”“ alienation,”
“world gets smaller,”“ avoidance,”“ hibernated state,”
“solitaire [sic],” and “withdrawn.” Subjects described the
need to avoid others in the following ways:
“I shut everybody out. I pick up my book, my book
goes in front of my face, and I don’t want to hear
anybody, don’t talk to me... Leave me alone and let
me live in my own little world for now. And that’s
what I do when I shut down” (severe).
I actually isolate myself. I isolate myself. I become
very withdrawn. I don’tl e a v e .Id o n ’t interact. I
don’tw a n tt og oo u t .Id o n ’t want to deal with any-
one (mild).
When discussing their avoidance, subjects described
themselves as avoiding people or situations, hiding,
sleeping, or staying in bed, avoiding self-care, avoiding
emotions, feeling safe at home, and losing communica-
tion with people, saying, for example:
It’s a very dark place... You do fall out of communi-
cation with people and you just kind of sit in bed
and lack the willpower to really get out there and do
what you need to do (moderate).
When describing a worst day with depression, subjects
indicated their need to be left alone, to avoid any inter-
actions or situations prompting interaction ("picking up
the phone,”). One patient, for example, reported that
when depressed:
“Id o n ’t feel like getting out of bed and facing the
world. I don’t feel like eating, I feel like burying my
head in the sand like an ostrich. And I just don’t feel
like - I’m just nervous around people. I don’tw a n t
to be around them” (remission).
Subjects were candid about suicide. Nine subjects in
three severe groups, both moderate groups, and one
each of the mild and remission groups discussed their
experiences with suicide attempts, describing the various
methods attempted (e.g., wrist cutting, swallowing pills,
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Page 9 of 14Table 2 Summary of Subjects’ Health Information
Criteria Focus
Group
Population
Focus Group Severity Content
Validation
Population
Content Validation Severity
Severe Moderate Mild In
Remission
Severe Moderate Mild In
Remission
Sample size 38 15 8 7 8 20 2 7 7 4
Health in general
Excellent 1 (2.6%) 0 0 0 1 4 (20.0%) 1 0 2 1
Very good 8 (21.1%) 1 3 2 2 5 (25.0%) 0 3 2 0
Good 12 (31.6%) 6 0 2 3 7 (35.0%) 0 3 2 2
Fair 11 (28.9%) 6 3 1 1 3 (15.0%) 1 0 1 1
Poor 3 (7.9%) 1 0 1 1 1 (5.0%) 0 1 0 0
Missing data 3 (7.9%) 1 2 0 0 0 (0%) 0 0 0 0
Comorbid conditions
Anxiety disorder 23 (60.5%) 12 3 4 4 9 (45.0%) 0 4 4 1
Arthritis 7 (18.4%) 4 0 2 1 2 (10.0%) 0 1 0 1
Cancer 1 (2.6%) 0 0 1 0 1 (5.0%) 0 1 0 0
Chronic headaches 4 (10.5%) 3 1 0 0 4 (20.0%) 0 1 2 1
Chronic low back pain 9 (23.7%) 5 2 0 2 6 (30.0%) 1 2 3 0
Colitis 0 (0%) 0 0 0 0 0 (0.0%) 0 0 0 0
Diabetes 3 (7.9%) 1 1 0 1 2 (10.0%) 0 1 0 1
Fibromyalgia 1 (2.6%) 1 0 0 0 1 (5.0%) 0 0 1 0
Heart or circulatory condition 1 (2.6%) 0 0 1 0 3 (15.0%) 0 1 1 1
Interstitial cystitis 0 (0%) 0 0 0 0 0 (0.0%) 0 0 0 0
Panic disorder 7 (18.4%) 4 1 1 1 3 (15.0%) 0 0 2 1
Thyroid disease 1 (2.6%) 1 0 0 0 2 (10.0%) 0 2 0 0
None 6 (15.8%) 2 3 0 1 4 (20.0%) 1 0 1 2
Other 9 (23.7%) 4 0 3 2 2 (10.0%) 0 0 1 1
Missing data 0 (0%) 0 0 0 0 1 (5.0%) 0 0 1 0
Type of care
ii
Care from a psychiatrist 31 (81.6%) 14 4 5 8 4 (20.0%) 1 2 0 1
Care from a psychologist 14 (36.8%) 8 4 2 5 4 (20.0%) 1 0 2 1
Care from a primary physician 12 (31.6%) 4 2 3 3 18 (90.0%) 1 7 6 4
Mental health clinic 5 (13.2%) 3 2 0 1 1 (5.0%) 0 0 0 1
Support group 7 (18.4%) 4 2 1 0 0 (0%) 0 0 0 0
Other (Therapist) 2 (5.3%) 0 0 0 2 0 (0%) 0 0 0 0
Other (NP) 1 (2.6%) 0 1 0 0 0 (0%) 0 0 0 0
Other (Hospital) 0 (0%) 0 0 0 0 1 (5.0%) 0 0 1 1
Other (Medication) 0 (0%) 0 0 0 0 1 (5.0%) 0 0 1 1
Missing data 3 (7.9%) 1 2 0 0 0 (0%) 0 0 0 0
Medication
ii
SSRI 17 (44.7%) 7 0 6 4 12 (60.0%) 1 3 6 2
NDRI 4 (10.5%) 3 1 0 0 3 (15.0%) 1 2 0 0
SNRI 12 (31.6%) 6 2 1 3 2 (10.0%) 0 0 1 1
Tricyclic 2 (5.3%) 1 0 0 1 0 (0.0%) 0 0 0 0
Tetracyclic 2 (5.3%) 1 0 1 0 0 (0.0%) 0 0 0 0
Atypical antipsychotic 5 (13.2%) 2 1 0 2 0 (0.0%) 0 0 0 0
Other (various) 10 (26.3%) 1 2 2 5 4 (20.0%) 0 2 1 1
Missing data 5 (13.2%) 2 3 0 0 1 (5.0%) 0 0 0 1
Years experiencing symptoms
< 1 year 1 (2.6%) 0 1 0 0 1 (5.0%) 0 0 0 0
1-5 years 6 (15.8%) 3 0 1 2 13 (65.0%) 0 0 0 0
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Page 10 of 14hanging self). At the time of their suicide attempt,
patients saw death as their “only option,” saying, for
example, “At those times it just... seem like there was no
way out” (mild) and “I finally decided that I just wanted
to give up, and I tried to take my life (severe).
MDD is described by subjects as a constellation of symp-
toms, including depressed mood (e.g., feeling sad), and
impacts. The complex, cluster-like presentation of MDD
became evident through subjects’ descriptions of symptoms
as impacts and vice versa (e.g., decreased concentration as
a symptom and/or impact of MDD). Following the analysis
of the transcripts from the focus groups, the comprehen-
sive list of symptoms and impacts spontaneously men-
tioned by subjects with MDD was reviewed and organized
into a conceptual framework (available upon request). A
draft patient-completed instrument was developed to
assess the symptoms and functional impairments asso-
ciated with MDD. While there are currently several clini-
cian-completed tools for diagnosis and management of
MDD, few, if any, capture the patients’ perspective.
Cognitive interviews of the MDD PRO
The first round of CIs of the 35-item questionnaire found
the items understandable, relevant, and readable on the
whole across severity groups. Several patients commen-
ted on the difficulty of using a 24-hour recall period for
concepts such as avoiding other people and those which
involved activities that may not occur every day. Some
items were changed from daily to weekly items due to
patient input that the symptom required a longer recall
period to capture variation and frequency. This resulted
in development of a daily and weekly PRO questionnaire.
Because both a daily and a weekly recall period were
tested, patients were specifically asked about the appro-
priateness of the recall period for each concept presented.
The choice of placing an item into the daily or weekly
questionnaire was a direct result of the patients’ prefer-
ence (relevance to day-to-day life) and ability to recall
changes which may occur with each concept over
24 hours or seven days.
The results of the second round of interviews were simi-
lar to the first in terms of understandability, relevance, and
readability, with added feedback regarding the questions
related to sleep and appetite changes. The results of the
third round of interviews were similar to previous rounds,
with few changes suggested except for changing some
daily items to weekly recall. Patients did suggest, for exam-
ple, that the item regarding losing interest in just about
everything be changed to be more specific (i.e., losing
interest in just about all activities) and that the recall per-
iod be changed from daily to weekly for this item. For
example, one patient stated, “Well, I guess lost interest in
just about everything - I’m just trying to think about what
everything would be. I guess I just was a little confused at
that.” Another patient indicated this question was difficult
to answer because “... I think it takes more than 24 hours
to just lose interest in everything.” The 11-point NRS,
instructions, and recall period were confirmed in the last
set of CIs.
Patients experienced and recognized the emotional
concepts (irritability, lack of pleasure, helplessness, anger,
crying, sadness, feeling overwhelmed, hopelessness, guilt,
lethargy, and anxiety), and felt they were well represented
in the questionnaires. Specific probing indicated that
although patients defined “helpless” and “hopeless” differ-
ently, their initial presentation as adjacent items led to
some confusion; moving the items further apart elimi-
nated the confusion between the two words. The concept
of “lack of pleasure” was tried in a number of item for-
mats, with one item “how much of the time have you felt
that you did not enjoy activities that you used to like to
do?” being chosen as the most preferred wording. Other
suggestions for wording were incorporated in order to
use patient words as much as possible.
The cognitive concepts (negative perceptions/thoughts,
problems with concentration/focus, memory problems,
clarity of thought, indecisiveness, and lack of confidence)
were also commonly experienced by patients and accepted
as important to the questionnaires. Specific wording from
patients helped to clarify the item on negative thoughts,
with “dwell on the negative” being well accepted and
understood to represent the concept. Suggestions for par-
enthetical examples for the concentration and memory
items were made by patients, and the changes were
Table 2 Summary of Subjects’ Health Information (Continued)
5-10 years 4 (10.5%) 1 0 2 1 2 (10.0%) 0 0 0 0
10-15 years 6 (15.8%) 2 2 1 1 3 (15.0%) 0 0 0 0
15-20 years 3 (7.9%) 2 0 1 0 0 (0.0%) 0 0 0 0
> 20 years* 13 (34.2%) 5 2 2 4 0 (0.0%) 0 0 0 0
Missing data 5 (13.2%) 2 3 0 0 1 (5.0%) 0 0 0 0
i: One subject dropped out of study during focus group
ii: Subjects were instructed to check all that apply; total will not equal 100%
*: Subjects who described how long they experienced their symptom with words such as: “forever,”“ most of my life,”“ many years,”“ very long time,” etc. are
included in this category
Note: Percentages (%) are rounded; each criterion (where appropriate) ≈ 100%x’
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Page 11 of 14confirmed by later CIs and led to patients interpreting the
items as intended.
The concepts of changes in eating and sleeping proved
more difficult to approach in the versions of the ques-
tionnaire tested, since different patients can have differ-
ent presentations, with either increased or decreased
sleeping or eating.
In summary, all daily items were changed after Round 1
to include the phrase, “In the past twenty-four hours,” at
the beginning of the question rather than the end to
focus attention on the recall period; likewise all weekly
items were also revised to include the phrase “In the past
7d a y s ” at the beginning of the question. Instructions
were changed after Rounds 1 and 2 to indicate the cor-
rect number of items in the questionnaire as items were
deleted. Six questions were moved from the daily to the
weekly recall period as patients’ reports indicated this
recall was more appropriate. Other changes were rela-
tively minor, such as rephrasing sentence wording to
more accurately reflect patients’ experience or patients’
words. For example, “In the past 7 days, how difficult has
it been for you to interact with close relatives?” was chan-
ged to, “In the past 7 days, how difficult has it been for
you to interact with close family members?” and “ener-
getic” was changed to “lack of energy.” In addition, the
order of some items was changed, such as moving the
items “helpless” and “hopeless” further apart in the ques-
tionnaire after patient input suggested their proximity
may be lead to confusion between the terms. Finally,
separate questions on “increases” and “decreases” in
appetite and sleep were created instead of using
“changes” in appetite or sleep.
Discussion
This MDD questionnaire is the first to date to be
developed through patient input in accordance with
the FDA’s Guidance for Industry: Patient-Reported
Outcome Measures [22]. The research reported here
produced data of high quality, given the rigorous data
collection, management, and analytic procedures, and
is of importance to the field of psychiatry because it
allows a window to witness the experiences of patients
suffering from a very debilitating disorder from the
patient’s voice and perspective. The content validity of
the MDD PRO was supported through analysis of both
the focus group and CI data; further support of its con-
tent validity, however, is required by means of psycho-
metric validation.
The design of this study, to start with focus groups
where the intent is to elicit breadth of concepts and to
conclude with individual in-depth CIs, allowed the con-
tent validity of the PRO MDD to be supported. This
study showed that patients with MDD are able to parti-
cipate in studies of this type, supporting the feasibility
of their responding to a questionnaire that can monitor
changes in their condition and that can be used to eval-
uate treatments. Only one person had to leave the focus
group due to the stress of this experience, and all parti-
cipants but two showed up for their group. A further
strength of this study is that the experience of MDD
was captured across severity levels, including mild, mod-
erate, severe, and in remission (partial and full), in order
to produce a measure that could capture worsening,
improvement, or the lack of change. Because few PRO
measures for depression have been developed with
documented patient input, a strong suit of this instru-
ment is that the exact words patients use to describe
the symptoms of MDD and their duration, frequency,
and severity, were elicited, as were the appropriate recall
periods for these symptoms. Items derived from these
concepts were tested during cognitive interviews. As
mentioned in the introduction, the importance of the
patient’s voice in the development of questionnaires to
measure treatment benefit increasingly has been empha-
sized and made public.
While this study has many strengths, one limitation of
this study is that the same group of patients was not fol-
lowed over time through episodes of major depression.
Although this cross-sectional approach of looking at
severity levels was efficient and in line with cost con-
straints, future research can use this instrument to
determine if it is responsive to changes in mental health
status over time. Future work should also address its
construct validity and its test-retest, and internal consis-
tency reliability. A further limitation is that the sample
is relatively highly educated; no patients in the CE or CI
interviews had less than a high school education. There
are no Hispanic or Latino patients in the focus groups
and no Native Americans; the absence of Native Ameri-
cans, however, may have been a function of the cities
from which we recruited, among other factors. It is to
be noted, however, that there was 7.9% missing data for
ethnicity in the focus group sample. The ethnic distribu-
tion of patients is more representative in the content
validity testing sample, which may attenuate any poten-
tial bias. One solution to this lack of representativeness
would be to test the content validity, validity, and relia-
bility of this instrument in diverse cultural groups.
Conclusion
The MDD PRO was developed with rigorous qualitative
research, and this research has supported its content
validity. Once it has undergone psychometric testing, it
can assist in recognizing MDD in patients of primary
care physicians, as well as in evaluating treatment bene-
fit of new targeted therapies. The MDD PRO has 35
items, 15 of which have a 24-hour recall period; the
remaining items have a seven-day recall period. Both
Lasch et al. BMC Psychiatry 2012, 12:34
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interviews and confirmed in the CIs. The MDD PRO is
a much-needed addition to measuring patient-reported
outcomes in patients suffering from this disabling
condition.
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